Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on: December 22,2023

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on:December 22,2023

FAM3C encapsulated in circulating tumor-derived extracellular vesicles promotes distant growth in lung cancers

byNational University of SingaporeTumor-derived EVs containing FAM3C trigger aggressiveness of lung carcinoma cells in vivo. (A) Tail vein injection of A549 lung carcinoma cells in mouse model a

Updated on: December 19,2023

FAM3C encapsulated in circulating tumor-derived extracellular vesicles promotes distant growth in lung cancers

byNational University of SingaporeTumor-derived EVs containing FAM3C trigger aggressiveness of lung carcinoma cells in vivo. (A) Tail vein injection of A549 lung carcinoma cells in mouse model a

Updated on:December 19,2023

Immune cell discovery opens door to new powerful cancer therapies

byUniversity College LondonCredit: CC0 Public DomainScientists at UCL have identified how a subset of immune cells are activated to kill cancerous cells, a finding in mice which could hold the k

Updated on: December 20,2023

Immune cell discovery opens door to new powerful cancer therapies

byUniversity College LondonCredit: CC0 Public DomainScientists at UCL have identified how a subset of immune cells are activated to kill cancerous cells, a finding in mice which could hold the k

Updated on:December 20,2023

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

byThe Mount Sinai HospitalCredit: Unsplash/CC0 Public DomainA clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improve

Updated on: October 23,2023

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

byThe Mount Sinai HospitalCredit: Unsplash/CC0 Public DomainA clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improve

Updated on:October 23,2023

A new mechanism of drug resistance discovered for breast cancer

by Universita Cattolica del Sacro CuoreEmergence of CSCs following IFN-I treatment.a, Multiparametric flow cytometry analysis of the illustrated CSC surface markers in MCA205 and AT3 cells treat

Updated on: December 21,2023

A new mechanism of drug resistance discovered for breast cancer

by Universita Cattolica del Sacro CuoreEmergence of CSCs following IFN-I treatment.a, Multiparametric flow cytometry analysis of the illustrated CSC surface markers in MCA205 and AT3 cells treat

Updated on:December 21,2023

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Updated on: October 15,2023

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Updated on:October 15,2023

Seeking leukemia's Achilles heel

byAmerican Society for Biochemistry and Molecular BiologyGraphical abstract. Credit:Molecular & Cellular Proteomics(2023). DOI: 10.1016/j.mcpro.2023.100503A team of researchers h

Updated on: December 17,2023

Seeking leukemia's Achilles heel

byAmerican Society for Biochemistry and Molecular BiologyGraphical abstract. Credit:Molecular & Cellular Proteomics(2023). DOI: 10.1016/j.mcpro.2023.100503A team of researchers h

Updated on:December 17,2023

Discovery of a protein controlling resistance to chemotherapy

byUniversité libre de BruxellesEMT is associated with intrinsic resistance to chemotherapy in SCCs. Credit:Nature(2023). DOI: 10.1038/s41586-023-05838-7Despite the recent development

Updated on: December 21,2023

Discovery of a protein controlling resistance to chemotherapy

byUniversité libre de BruxellesEMT is associated with intrinsic resistance to chemotherapy in SCCs. Credit:Nature(2023). DOI: 10.1038/s41586-023-05838-7Despite the recent development

Updated on:December 21,2023

AI model using daily step counts predicts unplanned hospitalizations during cancer therapy

byAmerican Society for Radiation OncologyCredit: Pixabay/CC0 Public DomainAn artificial intelligence (AI) model developed by researchers can predict the likelihood that a patient may have an unp

Updated on: January 04,2024

AI model using daily step counts predicts unplanned hospitalizations during cancer therapy

byAmerican Society for Radiation OncologyCredit: Pixabay/CC0 Public DomainAn artificial intelligence (AI) model developed by researchers can predict the likelihood that a patient may have an unp

Updated on:January 04,2024

Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial

byMayo ClinicCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenanc

Updated on: December 22,2023

Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial

byMayo ClinicCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenanc

Updated on:December 22,2023

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

Updated on: October 12,2023

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

Updated on:October 12,2023

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

November 22, 2022Caroline SeymourThe score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–sma

Updated on: October 17,2023

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

November 22, 2022Caroline SeymourThe score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–sma

Updated on:October 17,2023